The acquisition of remote cardiac monitoring company LifeWatch has been completed by BioTelemetry in a cash-and-stock deal worth $280 million. The company plans to expand into other areas of chronic care and "advance device innovation."
BioTelemetry announces completion of $280M LifeWatch acquisition
Sign up for AdvaMed SmartBrief
Medical technology news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.